<DOC>
	<DOC>NCT00312494</DOC>
	<brief_summary>3-week study to evaluate efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects</brief_summary>
	<brief_title>3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode manic (296.4x), or mixed (296.6x) as defined in Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSMIV TR) and determined by the Mini International Neuropsychiatric Interview (MINI). At screening and at baseline (within 12 hours prior to the first dose of doubleblind medication) subjects must have a Young Mania Rating Scale score of 18 or higher. Subjects must be actively receiving lithium or divalproex for their bipolar disorder in order to be considered for this study. Subjects with a Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSMIV TR) diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder not otherwise specified (NOS) (298.9). Subjects with other DSMIVTR Axis I or Axis II disorders (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6month period prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>